Structure Therapeutics, Inc. · NASDAQ:GPCR
Structure Therapeutics — Technical Presentation (December 2025)
47 slides from Structure Therapeutics's technical presentation, Dec 8, 2025
Slide 1: Aleniglipron Topline ACCESS Phase 2b Results
1 December 8, 2025 Aleniglipron Topline ACCESS Phase 2b Results
Slide 2: Forward-looking statements
2 This presentation contains “forward - looking statements” within the meaning of the “safe harbor” provisions of the Private Securi ties Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward - looking statements, including
Slide 3: Today's Update
3 Aleniglipron : A Backbone in Structure's Oral Small Molecule Portfolio Raymond Stevens Aleniglipron Phase 3 Readiness Blai Coll Topline 36 week Data from Phase 2b ACCESS and 3 Supplementary Studies Blai Coll, M.D., Ph.D, Chief Medical Officer Today’s Update Aleniglipron Obesity Opportunity Raymond
Slide 4: Our Mission: Making medicines more accessible to all
4 Our Mission Making medicines more accessible to all
Slide 5: Aleniglipron Obesity Opportunity
5 Aleniglipron Obesity Opportunity Raymond Stevens
Slide 6: Obesity market opportunity
6 1. August 2025 Symphony Health prescription data and 2025 Evaluate Pharma sales data 2. Trust for America’s Health Report https://www.tfah.org/report - details/stateofobesity2019/#:~:text=Obesity%20is%20a%20growing%20epidemic,100%20million%20people%20%E2%80%93%20have%20obes 3. Goldman Sachs Report
Slide 7: Aleniglipron: More Accessible, Scalable, and Combinable
7 Aleniglipron Represents a Potential Solution in Obesity Care to be More Accessible, Scalable, and Combinable Aleniglipron Oral Small Molecule Oral Peptides Injectable Peptides ADMINISTRATION Designed as o nce - daily pill, no fasting Once - daily pill, typically requires pre - dose fasting Once we
Slide 8: Aleniglipron Obesity Data Summary
8 Aleniglipron Obesity Data Summary Differentiated Selective Oral Small Molecule GLP - 1R Receptor Agonist Safety • > 500 participants treated across all studies up to 44 weeks o No events of drug induced liver injury o No off - target safety signals across all dose levels o No events of QTc prolong
Slide 9: Topline Week 36 Data: Phase 2b ACCESS and Three Supplementary Studies
9 Topline 36 Week Data Phase 2b ACCESS and Three Supplementary Studies Blai Coll
Slide 10: Multiple Aleniglipron Studies to Answer Key Questions
10 Multiple Aleniglipron Studies to Answer Key Questions Phase 2b ACCESS □ Assess Efficacy Tolerability, Safety up to 120 mg at 36 weeks Phase 3 Ready Chronic Weight Management ACCESS Open Label Extension Interim analysis to evaluate efficacy of 120mg up to 44 weeks Exploratory ACCESS II Evaluate ef
Slide 11: Phase 2b ACCESS Study Design
11 Phase 2b ACCESS Study Design Key S econdary Endpoints • % of participants who achieve ≥ 5%, ≥ 10% and ≥ 15% reduction in body weight at week 36 • Safety and tolerability profile of a monthly titration scheme Primary Endpoint • % change in body weight at week 36 compared to baseline (active vs. pl
Slide 12: Baseline Demographics and Characteristics (Phase 2b ACCESS)
12 Baseline Demographics and Characteristics (Phase 2b ACCESS) Placebo N=56 Aleniglipron 120 mg N=63 Aleniglipron 90 mg N=65 Aleniglipron 45 mg N=45 Characteristics Mean (SD) or N (%) 49.9 (15.8) 52.3 (13.9) 47.9 (12.5) 49.0 (12.7) Age, years, mean 30 (53.6) 35 (54.7) 35 (53.8) 25 (55.6) Sex, female
Slide 13: Aleniglipron Achieves Primary Efficacy Endpoint
13 • 11.3% placebo - adjusted mean weight loss at 36 weeks with 120 mg • Dose dependent body weight reduction observed from 45 to 120 mg • No signs of weight loss plateau through 36 weeks across all dose ranges Aleniglipron Achieves Primary Efficacy Endpoint (Phase 2b ACCESS) 27.3 lbs 24.3 lbs 20.3
Slide 14: Aleniglipron Achieved Secondary Efficacy Endpoints
14 Aleniglipron Achieved Secondary Efficacy Endpoints (Phase 2b ACCESS) • 86% of participants with 120 mg dose achieve at least 5% body weight reduction • 70% of participants with 120 mg dose achieve at least 10% body weight reduction • 38% of participants with 120 mg dose achieve at least 15% body
Slide 15: Prevalence of Nausea and Vomiting Events by Dose and Over Time
15 Prevalence of Nausea and Vomiting Events by Dose and Over Time (Phase 2b ACCESS) 45 mg (N=45) Placebo (N=56) 120 mg (N=63) 90 mg (N=65) • Highest nausea occurs in the first weeks of starting 5 mg dose titration, mostly mild to moderate • No increase in prevalence as participants titrate to higher
Slide 16: Cumulative Tolerability Profile Consistent with GLP-1RA Class
16 Cumulative Tolerability Profile Consistent with GLP - 1RA Class (Phase 2b ACCESS) Placebo N=56 Aleniglipron 120 mg N=63 Aleniglipron 90 mg N=65 Aleniglipron 45 mg N=45 N (%) Reporting at least one event * 5 mg 5 mg 5 mg Starting Dose 42 (75) 50 (78.1) 49 (75.4) 33 (73.3) Participants completed st
Slide 17: Summary: Aleniglipron Topline Phase 2b ACCESS Results
17 • 36 week placebo - adjusted mean weight loss : o 8.2% at 45 mg o 9.8% at 90 mg o 11.3% at 120 mg • No signs of weight loss plateau • 4 week titration to optimize tolerability: o GI - related AEs consistent with GLP - 1RA class o Overall 10.4% AE - related treatment discontinuations Summary Aleni
Slide 18: Multiple Aleniglipron Studies to Answer Key Questions
18 Multiple Aleniglipron Studies to Answer Key Questions Phase 2b ACCESS □ Assess Efficacy Tolerability, Safety up to 120 mg at 36 weeks Phase 3 Chronic Weight Management ACCESS Open Label Extension Interim analysis to evaluate efficacy of 120mg up to 44 - weeks Exploratory ACCESS II Evaluate effica
Slide 19: Is there weight loss plateau? ACCESS OLE Study Design
19 QUESTION: Is there weight loss plateau? ACCESS OLE Study Design Study Details N=230 Participants with: • Body mass index (BMI) ≥ 30 kg/m 2 or • BMI ≥ 27 kg/m 2 with ≥ 1 weight - related comorbidity Number of sites: 36 Weeks Baseline Titration Phase (every 4 weeks) Maintenance Phase (at target dos
Slide 20: ACCESS OLE: Additional Body Weight Reduction Beyond 36 Weeks
20 Phase 2b ACCESS (Week 0 - 36) ACCESS OLE * (Week 36 - 44) ANSWER: NO PLATEAU • Majority of eligible ACCESS participants enrolled in OLE • Weight loss continues to increase in all 4 arms of OLE through Week 44 • No evidence of weight loss plateau with transition to open label extension following W
Slide 21: Multiple Aleniglipron Studies to Answer Key Questions
21 Multiple Aleniglipron Studies to Answer Key Questions Phase 2b ACCESS □ Assess Efficacy Tolerability, Safety up to 120 mg at 36 weeks Phase 3 Chronic Weight Management ACCESS Open Label Extension Interim analysis to evaluate efficacy of 120mg up to 44 - weeks Exploratory ACCESS II Evaluate effica
Slide 22: Can we dose higher than 120 mg? Exploratory ACCESS II Study Design
22 240 mg 180 mg QUESTION: Can we dose higher than 120 mg? Exploratory ACCESS II Study Design Weeks 0 20 24 28 32 36 Baseline 180 mg 120 mg 90 mg 60 mg 30 mg 15 mg 5 mg Study details N=85 Participants with: • Body mass index (BMI) ≥ 30 kg/m 2 or • BMI ≥ 27 kg/m 2 with ≥ 1 weight - related comorbidit
Slide 23: Baseline Demographics and Characteristics (Exploratory ACCESS II)
23 Placebo N=12 Aleniglipron Overall N=61 Characteristics Mean (SD) or N (%) 51.8 (12.9) 49.8 (14.5) Age, years 8 (66.7) 38 (62.3) Sex, female 104.3 (12.38) 116.2 (31.9) Weight, kg 36.8 (5.1) 39.9 (8.4) Body mass index, kg/m 2 5.4 (0.36) 5.6 (0.35) HbA1c, % 122.6 (11.4) 122.2 (12.2) Systolic Blood P
Slide 24: Aleniglipron Achieved Greater Weight Loss with Higher Doses
24 Aleniglipron Achieved Greater Weight Loss with Higher Doses (Exploratory ACCESS II) Re - Randomization Titration Phase 180 mg and 240 mg Dose Phase Least - Squares Mean (LSM) Change (%) Body Weight
Slide 25: Greater Weight Loss with Higher Doses Post Re-randomization
25 Aleniglipron Achieves Greater Weight Loss with Higher Doses (Exploratory ACCESS II – Focusing on Post Re - randomization) Analysis on going - draft results - 14.1% ( - 19.0 to - 9.3) P<0.0001 180 mg and 240 mg Dose Phase - 14.4% ( - 19.1 to - 9.6) P<0.0001 - 15.3% ( - 20.1 to - 10.4) P<0.0001 LSM
Slide 26: Prevalence of Nausea by Dose Over Time (ACCESS II)
26 Prevalence of Nausea by Dose Over Time (Exploratory ACCESS II) Post Re - Randomization • Minimal number of participants with GI - events • 2 participants with intermittent events of nausea between weeks 33 - 36 SevereModerateMildSeverity Time from First Dose (Weeks) P e r c e n t a g e o f P a r
Slide 27: Prevalence of Vomiting by Dose Over Time (ACCESS II)
27 SevereModerateMildSeverity Time from First Dose (Weeks) P e r c e n t a g e o f P a r t i c i p a n t s ( % ) Post-re-randomization Vomiting Placebo (N=10)Post-re-randomization Vomiting Aleniglipron 240mg (N=9) Post-re-randomization Vomiting Aleniglipron 180mg (N=9)Post-re-randomization Vomiting
Slide 28: Cumulative Tolerability Results (Exploratory ACCESS II)
28 Cumulative Tolerability Results Consistent with GLP - 1RA Class (Exploratory ACCESS II) 180 mg and 240mg Dosing Phase (Re - randomized Study Ongoing) Titration Phase (Up to 120 mg) Placebo N=10 Aleniglipron 120 mg to 240 mg N=26 Placebo N=12 Aleniglipron Up to 120 mg N=61 N (%) Reporting at least
Slide 29: ANSWER: Additional activity confirmed up to 180 and 240 mg
29 ANSWER: Additional activity and weight loss directionality confirmed up to 180 and 240 mg • Directionality in efficacy (placebo - adjusted mean weight loss, 36 week ) o 14.1% at 120 mg o 14.4% at 180 mg o 15.3% at 240 mg • Proportionality in exposure • Tolerability o For those participants who ac
Slide 30: Multiple Aleniglipron Studies to Answer Key Questions
30 Multiple Aleniglipron Studies to Answer Key Questions Phase 2b ACCESS □ Assess Efficacy Tolerability, Safety up to 120 mg at 36 weeks Phase 3 Chronic Weight Management ACCESS Open Label Extension Interim analysis to evaluate efficacy of 120mg up to 44 - weeks Exploratory ACCESS II Evaluate effica
Slide 31: Will lower 2.5 mg starting dose improve tolerability? Study Design
31 Question: Will lower 2.5 mg starting dose further improve tolerability? OLE and Body Composition Study Design Body Composition Study Objectives • Evaluate tolerability with 2.5 mg starting dose • Assess body fat loss over 40 weeks to inform body composition endpoints in Phase 3 Study Details N=71
Slide 32: Baseline Demographics and Characteristics (Body Composition Study)
32 Baseline Demographics and Characteristics (Body Composition Study) Placebo N=12 Aleniglipron N=59 Characteristics Mean (SD) or N (%) 48.8 (16.4) 54.5 (11.4) Age, years, mean 8 (66.7) 38 (64.4) Sex, female 111.2 (20.8) 108.0 (20.2) Weight, kg 39.6 (6.8) 38.1 (6.2) Body mass index, kg/m 2 5.6 (0.3)
Slide 33: Prevalence of Nausea and Vomiting (Body Composition Study)
33 Prevalence of Nausea and Vomiting by Dose Over Time (Body Composition Study) SevereModerateMildSeverity Time from First Dose (Weeks) Nausea Placebo (N=12)Nausea Aleniglipron (N=59) 0 3 6 9 12 15 18 21 24 27 30 33 360 3 6 9 12 15 18 21 24 27 30 33 36 0 10 20 30 40 50 P e r c e n t a g e o f P a r
Slide 34: Cumulative Tolerability Results with 2.5 mg Starting Dose
34 Cumulative Aleniglipron Tolerability Results with 2.5 mg Starting Dose (Body Composition Study) Study Ongoing Placebo N=12 Aleniglipron N=59 N (%) Reporting at least one event 2.5 mg Starting Dose 9 (75.0) 42 (71.2) Any TEAE 0 0 Any TEAE leading to discontinuation of treatment 2 (16.7) 21 (35.6)
Slide 35: Aleniglipron Tolerability with 5 mg vs 2.5 mg Starting Dose
35 22 21.1 5.7 0 15.3 6.5 6.9 11.3 0 0 1.7 4.3 0 5 10 15 20 25 30 35 40 45 50 ACCESS 5 mg ACCESS-II 5 mg OLE 2.5 OLE 5 mg BC 2.5 mg BC 5 mg Nausea Vomiting Question: Will lower 2.5 mg starting dose further improve tolerability? Aleniglipron Tolerability with 5 mg vs 2.5 mg Starting Dose Percentage o
Slide 36: Aleniglipron Off-Target Safety Results
36 Aleniglipron Off - Target Safety Results Blai Coll
Slide 37: Aleniglipron Demonstrated Favorable Off-Target Safety Results
37 Aleniglipron Demonstrated Favorable Off - Target Safety Results Body Composition 2 Exploratory ACCESS II (up to 240 mg) ACCESS OLE 1 Phase 2b ACCESS (up to 120 mg) N (%) Placebo N=12 N=59 Placebo N=10 N=61 N=143 Placebo N=56 120 mg N=63 90 mg N=65 45 mg N=45 0 0 0 0 2 (1.4) 1 (1.8) 2 (3.2) 3 (4.8
Slide 38: Aleniglipron Obesity Data Summary
38 Aleniglipron Obesity Data Summary Differentiated Selective Oral GLP - 1R Small Molecule Agonist Safety • > 500 participants treated across all studies up to 44 weeks o No events of drug induced liver injury o No off - target safety signals across all dose levels o No events of QTc prolongation To
Slide 39: Aleniglipron Phase 3 Readiness
39 Aleniglipron Phase 3 Readiness Blai Coll
Slide 40: Compelling Data Package to Advance into Phase 3
40 Compelling Data Package to Advance into Phase 3* Manufacturing Phase 3 API manufacturing completed Phase 3 Drug Product manufacturing underway Next Step: Conduct End of Phase 2 meeting with FDA to confirm registrational Phase 3 program Phase 2b ACCESS Assess Efficacy Tolerability, Safety up to 12
Slide 41: Aleniglipron: A Backbone in Structure's Oral Small Molecule Portfolio
41 Aleniglipron: A Backbone in Structure's Oral Small Molecule Portfolio Raymond Stevens
Slide 42: Aleniglipron Positioned to Capture Growing Obesity Market
42 Aleniglipron is Differentiated and is Well Positioned to Capture a Significant Proportion of the Growing Obesity Market 2025 2026 2027 2028 2029 2030 Specialists Non - specialists Non - specialists = 75% Rx today and growing 3 Only > 5M patients on incretin treatment today in US 2 1. World Obesit
Slide 43: GLP-1RA and Amylin Oral Small Molecules as Backbones
43 GLP - 1RA and Amylin Oral Small Molecules Represent Backbones in our Future Oral Small Molecule Metabolic Portfolio Backbone + GCGR GLP - 1R + Amylin Backbones Combination Backbone + GIPR + GCGR Backbone + GIPR • Oral small molecule; once - daily dosing • Monotherapy backbone for chronic maintena
Slide 44: 2025: A Successful and Productive Year for Structure Therapeutics
44 Phase 3 Phase 2 Phase 1 Development Candidate/ IND - enabling Lead Optimization Discovery Study / Focus Molecule(s) Program ACCESS (+ OLE) Aleniglipron (GSBR - 1290) Selective GLP - 1 Receptor Agonist Backbone ACCESS II (+ Extension) Type 2 Diabetes SWITCH Study Body Composition ACCG - 2671 (DACR
Slide 45: $799M Cash with Multiple Anticipated Catalysts
45 $799M 1 Cash with Multiple Anticipated Catalysts Over the Next 12 Months □ Early 2H Initiation of pivotal Phase 3 study □ Topline results from SWITCH study □ Topline results from Type 2 Diabetes □ End of Phase 2 Meeting with FDA □ Topline results: □ ACCESS OLE □ ACCESS 2 Extension □ Body Composit
Slide 46: Our Mission: Making medicines more accessible to all
46 Our Mission Making medicines more accessible to all
Slide 47: Q&A
THERAPEUTICS Q&A
Structure Therapeutics — Technical Presentation (December 2025) on 6ix